Phase II trial of Didemnin B in previously treated non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group (ECOG) Study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 3, 2000, Pages 273-277

  Kucuk, Omer ^{a,b,c,d,e,f,g}   Young, Mary L ^a,b,c,d,e,f   Habermann, Thomas M ^a,b,c,d,e,f   Wolf, Barbara C ^a,b,c,d,e,f   Jimeno, Jose ^a,b,c,d,e,f   Cassileth, Peter A ^a,b,c,d,e,f  

^a WAYNE STATE UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e PHARMAMAR S A   (Spain)

^f UNIVERSITY OF MIAMI   (United States)

^g KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Didemnin B; Non Hodgkin's lymphoma

Indexed keywords

DIDEMNIN B; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; DEPSIPEPTIDE; DIDEMNINS;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PROGNOSIS; TREATMENT FAILURE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; REMISSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; REMISSION INDUCTION;

EID: 0034445547     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200006000-00013     Document Type: Article

References (23)

1. Marine natural products as sources of antiviral, antimicrobial and antineoplastic agents
2. Antiviral and antitumor compounds from tunicates
3. Antiviral and antitumor depsipeptides from a Caribbean tunicate
4. Didemnin B: A new immunosuppressive cyclic peptide with potent activity in vitro and in vivo
5. A comparison of the inhibitory effects of immunosuppressive agents cyclosporine, tetranactin, and didemnin B on human T cell responses in vitro
6. Biochemical and cellular effects of didemnins A and B
7. Antitumor activity of didemnin B in the human tumor stem cell assay
8. Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate
9. Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent
10. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates
11. Preclinical development of Aplidine, a novel marine derived compound with potent antitumor activity
12. Inhibition of T-lymphocyte proliferation bu the cyclic polypeptide didemnin B: No inhibition of lymphokine stimulation
13. Mechanism of action of didemnin B, a depsipeptide from the sea
14. GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha
15. Didemnin B in metastatic malignant melanoma: A phase II trial of the Southwest Oncology Group
16. Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer
17. Phase II clinical trial of didemnin B in previously treated small cell lung cancer
18. A phase II trial of didemnin B (NSC 335319) in patients with previously treated epithelial ovarian cancer
19. A phase II trial of didemnin B (NSC 335319) in patients with advanced squamous cell carcinoma of the cervix
20. A phase II trial of didemnin B in myeloma
21. Didemnin B in favourable histology non-Hodgkin's lymphoma
22. Non-parametric estimation for incomplete observations
23. Confidence limits for probability of response in multistage phase II clinical trials